Epigenetic biomarkers in urological tumors: A systematic review
Abstract Prostate, bladder, kidney and testis cancers, the most common genitourinary (GU) neoplasms, are generally clinically silent at their earliest stages when curative treatment is most likely successful. However, there are no consensual guidelines for GU cancer screening and available methods a...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2014-01, Vol.342 (2), p.264-274 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 274 |
|---|---|
| container_issue | 2 |
| container_start_page | 264 |
| container_title | Cancer letters |
| container_volume | 342 |
| creator | Jerónimo, Carmen Henrique, Rui |
| description | Abstract Prostate, bladder, kidney and testis cancers, the most common genitourinary (GU) neoplasms, are generally clinically silent at their earliest stages when curative treatment is most likely successful. However, there are no consensual guidelines for GU cancer screening and available methods are characterized by suboptimal sensitivity and specificity. Moreover, standard clinical and pathological parameters meet with important limitations in the assessment of prognosis in an individual basis. Herein, we focus on the development of epigenetic-based GU cancer biomarkers, which have emerged from exploratory studies in recent years and that hold the promise to revolutionize the clinical management of GU cancer patients. |
| doi_str_mv | 10.1016/j.canlet.2011.12.026 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1464910974</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0304383511007737</els_id><sourcerecordid>3401160531</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-acc1d0be61d97bce1992ecb849c8732860f052d6264183c3faa6d7f2f7cf54893</originalsourceid><addsrcrecordid>eNqFkU1r3DAQhkVoabZp_0EIhl56sauRZEvKISGE9AMCPbQ9C1keB21sayPZLfvvK7NJA7n0pMvzvqN5hpBToBVQaD5tK2enAeeKUYAKWEVZc0Q2oCQrpVb0FdlQTkXJFa-PyduUtpTSWsj6DTlmDLQSim3I5c3O3-GEs3dF68No4z3GVPipWGIYwp13dijmZQwxnRdXRdqnGUe70hF_e_zzjrzu7ZDw_eN7Qn59vvl5_bW8_f7l2_XVbemEqOfSOgcdbbGBTsvWIWjN0LVKaKckZ6qhPa1Z17BGgOKO99Y2nexZL11fC6X5Cfl46N3F8LBgms3ok8NhsBOGJRkQjdBAtRQZ_fAC3YYlTvl3BuqaKZ1BmSlxoFwMKUXszS76vP7eADWrYLM1B8FmFWyAmSw4x84ey5d2xO5f6MloBi4OAGYb2VA0yXmcHHY-optNF_z_JrwscIOf1jvc4x7T8y4m5YD5sR55vTEApVJyyf8CUtahxg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1552894917</pqid></control><display><type>article</type><title>Epigenetic biomarkers in urological tumors: A systematic review</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Jerónimo, Carmen ; Henrique, Rui</creator><creatorcontrib>Jerónimo, Carmen ; Henrique, Rui</creatorcontrib><description>Abstract Prostate, bladder, kidney and testis cancers, the most common genitourinary (GU) neoplasms, are generally clinically silent at their earliest stages when curative treatment is most likely successful. However, there are no consensual guidelines for GU cancer screening and available methods are characterized by suboptimal sensitivity and specificity. Moreover, standard clinical and pathological parameters meet with important limitations in the assessment of prognosis in an individual basis. Herein, we focus on the development of epigenetic-based GU cancer biomarkers, which have emerged from exploratory studies in recent years and that hold the promise to revolutionize the clinical management of GU cancer patients.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2011.12.026</identifier><identifier>PMID: 22198482</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Animals ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; DNA Methylation ; Epigenesis, Genetic ; Epigenetic-based biomarkers ; Gene Expression Regulation, Neoplastic ; Genetic Predisposition to Disease ; Genetic Testing ; Genitourinary cancer ; Hematology, Oncology and Palliative Medicine ; Histone modifications ; Histones - metabolism ; Humans ; microRNAs ; MicroRNAs - genetics ; Mortality ; Phenotype ; Predictive Value of Tests ; Prognosis ; Prostate cancer ; Systematic review ; Testicular cancer ; Tumors ; Urologic Neoplasms - diagnosis ; Urologic Neoplasms - genetics ; Urologic Neoplasms - metabolism ; Urologic Neoplasms - therapy</subject><ispartof>Cancer letters, 2014-01, Vol.342 (2), p.264-274</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2011 Elsevier Ireland Ltd</rights><rights>Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jan 28, 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-acc1d0be61d97bce1992ecb849c8732860f052d6264183c3faa6d7f2f7cf54893</citedby><cites>FETCH-LOGICAL-c445t-acc1d0be61d97bce1992ecb849c8732860f052d6264183c3faa6d7f2f7cf54893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.canlet.2011.12.026$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22198482$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jerónimo, Carmen</creatorcontrib><creatorcontrib>Henrique, Rui</creatorcontrib><title>Epigenetic biomarkers in urological tumors: A systematic review</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Abstract Prostate, bladder, kidney and testis cancers, the most common genitourinary (GU) neoplasms, are generally clinically silent at their earliest stages when curative treatment is most likely successful. However, there are no consensual guidelines for GU cancer screening and available methods are characterized by suboptimal sensitivity and specificity. Moreover, standard clinical and pathological parameters meet with important limitations in the assessment of prognosis in an individual basis. Herein, we focus on the development of epigenetic-based GU cancer biomarkers, which have emerged from exploratory studies in recent years and that hold the promise to revolutionize the clinical management of GU cancer patients.</description><subject>Animals</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>DNA Methylation</subject><subject>Epigenesis, Genetic</subject><subject>Epigenetic-based biomarkers</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genetic Predisposition to Disease</subject><subject>Genetic Testing</subject><subject>Genitourinary cancer</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Histone modifications</subject><subject>Histones - metabolism</subject><subject>Humans</subject><subject>microRNAs</subject><subject>MicroRNAs - genetics</subject><subject>Mortality</subject><subject>Phenotype</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Prostate cancer</subject><subject>Systematic review</subject><subject>Testicular cancer</subject><subject>Tumors</subject><subject>Urologic Neoplasms - diagnosis</subject><subject>Urologic Neoplasms - genetics</subject><subject>Urologic Neoplasms - metabolism</subject><subject>Urologic Neoplasms - therapy</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1r3DAQhkVoabZp_0EIhl56sauRZEvKISGE9AMCPbQ9C1keB21sayPZLfvvK7NJA7n0pMvzvqN5hpBToBVQaD5tK2enAeeKUYAKWEVZc0Q2oCQrpVb0FdlQTkXJFa-PyduUtpTSWsj6DTlmDLQSim3I5c3O3-GEs3dF68No4z3GVPipWGIYwp13dijmZQwxnRdXRdqnGUe70hF_e_zzjrzu7ZDw_eN7Qn59vvl5_bW8_f7l2_XVbemEqOfSOgcdbbGBTsvWIWjN0LVKaKckZ6qhPa1Z17BGgOKO99Y2nexZL11fC6X5Cfl46N3F8LBgms3ok8NhsBOGJRkQjdBAtRQZ_fAC3YYlTvl3BuqaKZ1BmSlxoFwMKUXszS76vP7eADWrYLM1B8FmFWyAmSw4x84ey5d2xO5f6MloBi4OAGYb2VA0yXmcHHY-optNF_z_JrwscIOf1jvc4x7T8y4m5YD5sR55vTEApVJyyf8CUtahxg</recordid><startdate>20140128</startdate><enddate>20140128</enddate><creator>Jerónimo, Carmen</creator><creator>Henrique, Rui</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20140128</creationdate><title>Epigenetic biomarkers in urological tumors: A systematic review</title><author>Jerónimo, Carmen ; Henrique, Rui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-acc1d0be61d97bce1992ecb849c8732860f052d6264183c3faa6d7f2f7cf54893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>DNA Methylation</topic><topic>Epigenesis, Genetic</topic><topic>Epigenetic-based biomarkers</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genetic Predisposition to Disease</topic><topic>Genetic Testing</topic><topic>Genitourinary cancer</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Histone modifications</topic><topic>Histones - metabolism</topic><topic>Humans</topic><topic>microRNAs</topic><topic>MicroRNAs - genetics</topic><topic>Mortality</topic><topic>Phenotype</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Prostate cancer</topic><topic>Systematic review</topic><topic>Testicular cancer</topic><topic>Tumors</topic><topic>Urologic Neoplasms - diagnosis</topic><topic>Urologic Neoplasms - genetics</topic><topic>Urologic Neoplasms - metabolism</topic><topic>Urologic Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jerónimo, Carmen</creatorcontrib><creatorcontrib>Henrique, Rui</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jerónimo, Carmen</au><au>Henrique, Rui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epigenetic biomarkers in urological tumors: A systematic review</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2014-01-28</date><risdate>2014</risdate><volume>342</volume><issue>2</issue><spage>264</spage><epage>274</epage><pages>264-274</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Abstract Prostate, bladder, kidney and testis cancers, the most common genitourinary (GU) neoplasms, are generally clinically silent at their earliest stages when curative treatment is most likely successful. However, there are no consensual guidelines for GU cancer screening and available methods are characterized by suboptimal sensitivity and specificity. Moreover, standard clinical and pathological parameters meet with important limitations in the assessment of prognosis in an individual basis. Herein, we focus on the development of epigenetic-based GU cancer biomarkers, which have emerged from exploratory studies in recent years and that hold the promise to revolutionize the clinical management of GU cancer patients.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>22198482</pmid><doi>10.1016/j.canlet.2011.12.026</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2014-01, Vol.342 (2), p.264-274 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1464910974 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism DNA Methylation Epigenesis, Genetic Epigenetic-based biomarkers Gene Expression Regulation, Neoplastic Genetic Predisposition to Disease Genetic Testing Genitourinary cancer Hematology, Oncology and Palliative Medicine Histone modifications Histones - metabolism Humans microRNAs MicroRNAs - genetics Mortality Phenotype Predictive Value of Tests Prognosis Prostate cancer Systematic review Testicular cancer Tumors Urologic Neoplasms - diagnosis Urologic Neoplasms - genetics Urologic Neoplasms - metabolism Urologic Neoplasms - therapy |
| title | Epigenetic biomarkers in urological tumors: A systematic review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T02%3A54%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epigenetic%20biomarkers%20in%20urological%20tumors:%20A%20systematic%20review&rft.jtitle=Cancer%20letters&rft.au=Jer%C3%B3nimo,%20Carmen&rft.date=2014-01-28&rft.volume=342&rft.issue=2&rft.spage=264&rft.epage=274&rft.pages=264-274&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2011.12.026&rft_dat=%3Cproquest_cross%3E3401160531%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1552894917&rft_id=info:pmid/22198482&rft_els_id=1_s2_0_S0304383511007737&rfr_iscdi=true |